https://www.live-feeds.com/feed/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-winContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-winhttps://www.live-feeds.com/feed/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-win#u63662Thu, 10 Sep 2026 07:11:00 +0000Roivant secured a phase 2 win after investing $14 million in an experimental inhaled hypertension and lung disease medication acquired from Bayer. The mid-stage clinical study successfully met its primary goals. This positive outcome drove gains for the company, sending biotech stocks soaring to record highs amid strong investor enthusiasm. The treatment targets pulmonary hypertension associated with interstitial lung disease.Why it mattersThe mid-stage success validates a targeted financial strategy by Roivant to acquire and develop promising clinical assets from larger pharmaceutical firms.